163 related articles for article (PubMed ID: 32394097)
1. In vivo assessment of the drug interaction between sorafenib and paracetamol in rats.
Karbownik A; Sobańska K; Grabowski T; Stanisławiak-Rudowicz J; Wolc A; Grześkowiak E; Szałek E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1039-1048. PubMed ID: 32394097
[TBL] [Abstract][Full Text] [Related]
2. The concomitant use of lapatinib and paracetamol - the risk of interaction.
Karbownik A; Szałek E; Sobańska K; Grabowski T; Klupczynska A; Plewa S; Wolc A; Magiera M; Porażka J; Kokot ZJ; Grześkowiak E
Invest New Drugs; 2018 Oct; 36(5):819-827. PubMed ID: 29464465
[TBL] [Abstract][Full Text] [Related]
3. In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol.
Karbownik A; Miedziaszczyk M; Grabowski T; Stanisławiak-Rudowicz J; Jaźwiec R; Wolc A; Grześkowiak E; Szałek E
Biomed Pharmacother; 2020 Oct; 130():110530. PubMed ID: 32712531
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood-Brain Barrier in Rats.
Karbownik A; Stanisławiak-Rudowicz J; Stachowiak A; Romański M; Grześkowiak E; Szałek E
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):801-808. PubMed ID: 32776310
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice.
Karbownik A; Szałek E; Sobańska K; Grabowski T; Wolc A; Grześkowiak E
Eur J Pharm Sci; 2017 May; 102():55-62. PubMed ID: 28232141
[TBL] [Abstract][Full Text] [Related]
6. The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats.
Karbownik A; Stachowiak A; Urjasz H; Sobańska K; Szczecińska A; Grabowski T; Stanisławiak-Rudowicz J; Wolc A; Grześkowiak E; Szałek E
Pharmacol Rep; 2020 Feb; 72(1):254-259. PubMed ID: 32016844
[TBL] [Abstract][Full Text] [Related]
7. Influence of the Time of Intravenous Administration of Paracetamol on its Pharmacokinetics and Ocular Disposition in Rabbits.
Karbownik A; Bienert A; Płotek W; Grabowski T; Cerbin-Koczorowska M; Wolc A; Grześkowiak E
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):489-498. PubMed ID: 27485347
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats.
Ali BH; Cheng Z; el Hadrami G; Bashir AK; McKellar QA
J Vet Pharmacol Ther; 1996 Jun; 19(3):238-44. PubMed ID: 8803883
[TBL] [Abstract][Full Text] [Related]
9. Effect of niprisan on single oral dose pharmacokinetics of paracetamol in rats.
Adzu B; Garba M; Haruna A; Maman M; Wambebe C; Gamaniel K
Eur J Drug Metab Pharmacokinet; 2001; 26(3):201-4. PubMed ID: 11695721
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous paracetamol in elderly patients.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Niemi M; Neuvonen PJ; Olkkola KT
Clin Pharmacokinet; 2011 Feb; 50(2):121-9. PubMed ID: 21241071
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of paracetamol in patients with chronic pancreatitis.
Siepsiak M; Szałek E; Karbownik A; Grabowski T; Mziray M; Adrych K; Grześkowiak E
Pharmacol Rep; 2016 Aug; 68(4):733-6. PubMed ID: 27127912
[TBL] [Abstract][Full Text] [Related]
12. The contributions of various chloroquine salts to the biliary and urinary execretion of hepatic paracetamol conjugation metabolites in the rat.
Oforah E; Anyogo S
Drug Metabol Drug Interact; 2000; 16(2):129-41. PubMed ID: 10962645
[TBL] [Abstract][Full Text] [Related]
13. Systemic exposure of Paracetamol (acetaminophen) was enhanced by quercetin and chrysin co-administration in Wistar rats and in vitro model: risk of liver toxicity.
Pingili RB; Pawar AK; Challa SR
Drug Dev Ind Pharm; 2015; 41(11):1793-800. PubMed ID: 25678313
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan.
Bienert A; Kamińska A; Olszewski J; Gracz J; Grabowski T; Wolc A; Grześkowiak E
Pharmacol Rep; 2012; 64(2):421-7. PubMed ID: 22661194
[TBL] [Abstract][Full Text] [Related]
15. THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS.
Karbownik A; Polom W; Porazka J; Szalek E; Grabowski T; Wolc A; Matuszewski Marcin ; Grzesowiak E
Acta Pol Pharm; 2017 May; 74(3):929-935. PubMed ID: 29513963
[TBL] [Abstract][Full Text] [Related]
16. Effect of nizatidine on paracetamol and its metabolites in human plasma.
Itoh H; Nagano T; Takeyama M
J Pharm Pharmacol; 2002 Jun; 54(6):869-73. PubMed ID: 12079004
[TBL] [Abstract][Full Text] [Related]
17. Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva.
Issa MM; Nejem RM; El-Abadla NS
Clin Drug Investig; 2006; 26(4):223-6. PubMed ID: 17163255
[TBL] [Abstract][Full Text] [Related]
18. Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat.
Yeung JH; Chiu LC; Ooi VE
Eur J Drug Metab Pharmacokinet; 1995; 20(4):287-92. PubMed ID: 8983934
[TBL] [Abstract][Full Text] [Related]
19. The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model.
Chiew A; Day P; Salonikas C; Naidoo D; Graudins A; Thomas R
Emerg Med Australas; 2010 Dec; 22(6):548-55. PubMed ID: 21143403
[TBL] [Abstract][Full Text] [Related]
20. Paracetamol and metabolite pharmacokinetics in infants.
van der Marel CD; Anderson BJ; van Lingen RA; Holford NH; Pluim MA; Jansman FG; van den Anker JN; Tibboel D
Eur J Clin Pharmacol; 2003 Jul; 59(3):243-51. PubMed ID: 12761605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
